Editorial: Safety of Tumor Necrosis Factor Inhibitors in Pregnancy

Affiliations

Editorial

Janet E Pope. Arthritis Rheumatol. 2018 Sep.

. 2018 Sep;70(9):1359-1363.

doi: 10.1002/art.40540. Epub 2018 Jul 23.

¹ St. Joseph's Health Care, University of Western Ontario, London, Ontario, Canada.

No abstract available

Comment in

Reply.
Pope JE. Pope JE. Arthritis Rheumatol. 2019 May;71(5):834-835. doi: 10.1002/art.40836. Epub 2019 Mar 20. Arthritis Rheumatol. 2019. PMID: 30636095 No abstract available.
More Comprehensive Considerations in Assessing the Safety of Treatments During Pregnancy: Comment on the Editorial by Pope.
Sánchez-Pernaute O. Sánchez-Pernaute O. Arthritis Rheumatol. 2019 May;71(5):833-834. doi: 10.1002/art.40837. Epub 2019 Mar 20. Arthritis Rheumatol. 2019. PMID: 30636110 No abstract available.

Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.
Clowse MEB, Scheuerle AE, Chambers C, Afzali A, Kimball AB, Cush JJ, Cooney M, Shaughnessy L, Vanderkelen M, Förger F. Clowse MEB, et al. Arthritis Rheumatol. 2018 Sep;70(9):1399-1407. doi: 10.1002/art.40508. Epub 2018 Jul 22. Arthritis Rheumatol. 2018. PMID: 29623679 Free PMC article.